Skip to content
MarketScale
‹ Back to IndustriesSciences

Fiberguide Established an International Network of Distributors to Better Serve Our Customers

For over forty years Fiberguide Industries has built a reputation as a reliable, long-term, strategic partner with Original Equipment Manufacturers by providing cost-effective, practical fiber optic solutions engineered to meet a client’s specific needs. However, that’s not the only partnership that has contributed to the company’s success. Fiberguide is proud to have an extensive international…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Promoted Content · Fiberguide ArticlePromoted Content
Share
Fiberguide Established an International Network of Distributors to Better Serve Our Customers

Key takeaways

01

For over forty years Fiberguide Industries has built a reputation as a reliable, long-term, strategic partner with Original Equipment Manufacturers by providing cost-effective, practical fiber optic solutions engineered to meet a client’s specific needs.

02

However, that’s not the only partnership that has contributed to the company’s success.

03

Fiberguide is proud to have an extensive international…

For over forty years Fiberguide Industries has built a reputation as a reliable, long-term, strategic partner with Original Equipment Manufacturers by providing cost-effective, practical fiber optic solutions engineered to meet a client’s specific needs. However, that’s not the only partnership that has contributed to the company’s success. Fiberguide is proud to have an extensive international network of distribution partners. These partners expand the reach of Fiberguide to better address the needs of current and future clients with innovative solutions.

Fiberguide Begins Life as a National Company

In 1977, when Ted Rich founded Fiberguide in New Jersey, he may not have envisioned the international reach the company would eventually have. Rich established Fiberguide as a specialty optical fiber manufacturer producing both non-standard fibers and specially coated fibers for the nuclear, medical, industrial, and energy industries. As demand grew, Fiberguide merged with Highlight Fiber Optics in Idaho, later opening a state-of-the-art CNC Machining Center there. This new center marked a significant expansion for Fiberguide, but that was just the beginning.

The Company Expands to Serve an International Audience

Since the 1990s, Fiberguide has been expanding its network of distributors around the globe in order to serve an expanding international client base better. The company opened a Chinese sales office in 2010, followed by a manufacturing facility in Shanghai in 2012. This location manufactures, stocks, and ships products to Chinese customers, thus reducing transport and customs complications. The Shanghai expansion marked the beginning of a direct international presence with more to come. In 2018, for example, an account manager was added in Europe to serve customers better.

A Global Network of Distributors to Address Client’s Needs

Today, the strong network of global distributors has the technological expertise to provide all of Fiberguide’s products and services to customers. Each of these partners is assigned a Fiberguide manager who regularly visits to answer questions and provide training. Clients can call their local distributor at any time without any concerns about differences in time zones, or visit their nearby office to view products or have a meeting. And if a client has a custom order, their local distributor can draw on the expertise of Fiberguide engineers to deliver an innovative solution.

Fiberguide’s reliable network of distributors in the United States and overseas allows us to serve global consumers and corporations at the local level. To find the contact information for the distributor nearest you, visit our interactive distributor map at https://www.fiberguide.com/distributors.

Read more at fiberguide.com

About the author

PC
Promoted Content

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

PC
Promoted Content

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512